Thermo Fisher Scientific Inc. $TMO Stake Lifted by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,500 shares of the medical research company’s stock after buying an additional 1,500 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Thermo Fisher Scientific were worth $3,041,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sage Mountain Advisors LLC boosted its stake in Thermo Fisher Scientific by 6.3% in the 2nd quarter. Sage Mountain Advisors LLC now owns 2,580 shares of the medical research company’s stock worth $1,046,000 after purchasing an additional 153 shares during the period. Washington Trust Advisors Inc. lifted its stake in shares of Thermo Fisher Scientific by 1.6% in the 2nd quarter. Washington Trust Advisors Inc. now owns 2,711 shares of the medical research company’s stock valued at $1,099,000 after purchasing an additional 44 shares during the last quarter. DDD Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $9,641,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Thermo Fisher Scientific by 0.5% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,123,862 shares of the medical research company’s stock valued at $455,681,000 after purchasing an additional 5,483 shares during the last quarter. Finally, MN Wealth Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 10.8% in the 2nd quarter. MN Wealth Advisors LLC now owns 658 shares of the medical research company’s stock valued at $267,000 after purchasing an additional 64 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $573.07 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a market cap of $216.40 billion, a P/E ratio of 33.11, a PEG ratio of 3.24 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The company’s 50-day simple moving average is $504.04 and its 200 day simple moving average is $453.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same period in the prior year, the business earned $5.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,666 shares of company stock worth $13,990,971. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on TMO. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Robert W. Baird boosted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. JPMorgan Chase & Co. boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating for the company. Finally, Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday. Nineteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $595.75.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.